Compare AAOI & ABVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | AAOI | ABVX |
|---|---|---|
| Founded | 1997 | 2013 |
| Country | United States | France |
| Employees | N/A | N/A |
| Industry | Semiconductors | |
| Sector | Technology | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 14.8B | 11.9B |
| IPO Year | 2013 | 2022 |
| Metric | AAOI | ABVX |
|---|---|---|
| Price | $106.25 | $89.05 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 12 |
| Target Price | $163.40 | ★ $164.00 |
| AVG Volume (30 Days) | ★ 6.4M | 1.3M |
| Earning Date | 11-05-2026 | 09-21-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 85.78 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $127.87 | N/A |
| Revenue Next Year | $156.48 | $1,702.77 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $18.50 | $69.81 |
| 52 Week High | $233.67 | $148.83 |
| Indicator | AAOI | ABVX |
|---|---|---|
| Relative Strength Index (RSI) | 47.77 | 30.25 |
| Support Level | $95.70 | $74.79 |
| Resistance Level | $115.46 | $128.68 |
| Average True Range (ATR) | 7.57 | 4.08 |
| MACD | 2.37 | -0.74 |
| Stochastic Oscillator | 32.80 | 14.97 |
Applied Optoelectronics Inc is a provider of fiber-optic networking products, for four networking end-markets; internet data center, CATV, telecom, and FTTH. The Company designs and manufactures a wide range of optical communications products at varying levels of integration, from components, subassemblies, and modules to meet turn-key equipment. Through direct sales personnel, and manufacturing teams in the United States, China, and Taiwan, the company coordinates with customers to determine product design, qualifications, and performance. The Company has manufacturing and research and development facilities located in the U.S., Taiwan, and China.
Abivax SA is a France-based clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. The company is evaluating its drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis. Its initial focus is on inflammatory bowel diseases, chronic conditions involving inflammation of the gastrointestinal tract, of which the two common forms are UC and CD. The Group operates in a single operating segment: R&D of pharmaceutical products in order to market them in the future.